| Product Code: ETC7665504 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Israel mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Israel mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.7 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 Israel mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing research and development activities in mRNA vaccines and RNAi therapeutics in Israel |
4.2.2 Growing investment in healthcare infrastructure and biotechnology sector |
4.2.3 Rising prevalence of chronic diseases driving the demand for innovative treatments |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and approval processes for mRNA vaccines and RNAi therapeutics |
4.3.2 Limited awareness and acceptance of mRNA vaccines and RNAi therapeutics among healthcare professionals and patients |
5 Israel mRNA Vaccines and RNAi Therapeutics Market Trends |
6 Israel mRNA Vaccines and RNAi Therapeutics Market, By Types |
6.1 Israel mRNA Vaccines and RNAi Therapeutics Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F |
6.1.4 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F |
6.1.5 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F |
6.1.6 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F |
6.2 Israel mRNA Vaccines and RNAi Therapeutics Market, By Administration |
6.2.1 Overview and Analysis |
6.2.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F |
6.2.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.3 Israel mRNA Vaccines and RNAi Therapeutics Market, By End user |
6.3.1 Overview and Analysis |
6.3.2 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.3.3 Israel mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
7 Israel mRNA Vaccines and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 Israel mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries |
7.2 Israel mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries |
8 Israel mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
8.1 Research and development expenditure in mRNA vaccines and RNAi therapeutics |
8.2 Number of clinical trials conducted for mRNA vaccines and RNAi therapeutics in Israel |
8.3 Adoption rate of mRNA vaccines and RNAi therapeutics by healthcare institutions and practitioners |
9 Israel mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
9.1 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.3 Israel mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 Israel mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
10.1 Israel mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Israel mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here